tiprankstipranks
Advertisement
Advertisement

GB:0QAJ Stock Latest News

DBV Technologies price target raised to $47 from $45 at Citizens
The FlyDBV Technologies price target raised to $47 from $45 at Citizens
6h ago
DBVT
Dbv Technologies SA (UK) (0QAJ) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Dbv Technologies SA (UK) (0QAJ) Q4 Earnings Cheat Sheet
24d ago
DBV Technologies announces Phase 3 Vitesse trial met primary endpoint
PremiumThe Fly
DBV Technologies announces Phase 3 Vitesse trial met primary endpoint
26d ago
DBVT
Midday Fly By: Warner Bros. urges investors to reject Paramount bid
PremiumThe Fly
Midday Fly By: Warner Bros. urges investors to reject Paramount bid
3M ago
PG
ABM
DBV Technologies price target raised to $40 from $35 at H.C. Wainwright
PremiumThe Fly
DBV Technologies price target raised to $40 from $35 at H.C. Wainwright
3M ago
DBVT
DBV Technologies price target raised to $48 from $42 at Cantor Fitzgerald
PremiumThe FlyDBV Technologies price target raised to $48 from $42 at Cantor Fitzgerald
3M ago
DBVT
Optimistic Buy Recommendation for DBV Technologies Driven by Viaskin Peanut’s Strong Clinical Results and Market Potential
Premium
Ratings
Optimistic Buy Recommendation for DBV Technologies Driven by Viaskin Peanut’s Strong Clinical Results and Market Potential
3M ago
DBVT
DBV Technologies price target raised to $51 from $35 at Guggenheim
Premium
The Fly
DBV Technologies price target raised to $51 from $35 at Guggenheim
3M ago
DBVT
DBV Technologies price target raised to $45 from $21 at Citizens
PremiumThe Fly
DBV Technologies price target raised to $45 from $21 at Citizens
3M ago
DBVT
DBV Technologies trading resumes, shares up 65% to $29.60
PremiumThe Fly
DBV Technologies trading resumes, shares up 65% to $29.60
3M ago
DBVT
DBV Technologies jumps 79% after peanut allergy study hits endpoint
PremiumThe Fly
DBV Technologies jumps 79% after peanut allergy study hits endpoint
3M ago
DBVT
DBV Technologies trading resumes
PremiumThe Fly
DBV Technologies trading resumes
3M ago
DBVT
DBV Technologies reports VITESSE trial meets primary endpoint
PremiumThe FlyDBV Technologies reports VITESSE trial meets primary endpoint
3M ago
DBVT
DBV Technologies trading halted, news pending
Premium
The Fly
DBV Technologies trading halted, news pending
3M ago
DBVT
DBV Technologies initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
DBV Technologies initiated with an Overweight at Cantor Fitzgerald
3M ago
DBVT
DBV Technologies price target raised to $35 from $20 at H.C. Wainwright
PremiumThe Fly
DBV Technologies price target raised to $35 from $20 at H.C. Wainwright
3M ago
DBVT
DBV Technologies initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
DBV Technologies initiated with an Overweight at Cantor Fitzgerald
3M ago
DBVT
Guggenheim starts DBV Technologies at Buy on peanut allergy market potential
PremiumThe Fly
Guggenheim starts DBV Technologies at Buy on peanut allergy market potential
4M ago
DBVT
DBV Technologies initiated with a Buy at Guggenheim
PremiumThe Fly
DBV Technologies initiated with a Buy at Guggenheim
4M ago
DBVT
Optimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments
PremiumRatingsOptimistic Buy Rating for DBV Technologies Amid Promising VIASKIN Peanut Trial Developments
4M ago
DBVT
DBV Technologies announces last patient visit completed in VITESSE trial
Premium
The Fly
DBV Technologies announces last patient visit completed in VITESSE trial
5M ago
DBVT
DBV Technologies appoints Kevin Trapp as chief commercial officer
Premium
The Fly
DBV Technologies appoints Kevin Trapp as chief commercial officer
5M ago
DBVT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >